Get the Stockscreener App
0.4972
2.09%
-0.0106
Pre-market:
.49
-0.0072
-1.45%
Outlook Therapeutics Inc stock is traded at $0.4972, with a volume of 1.81M.
It is down -2.09% in the last 24 hours and down -72.68% over the past month.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$0.5078
Open:
$0.51
24h Volume:
1.81M
Relative Volume:
0.29
Market Cap:
$31.88M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.1243
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-4.38%
1M Performance:
-72.68%
6M Performance:
-75.63%
1Y Performance:
-73.55%
1-Day Range:
$0.481
$0.5184
1-Week Range:
$0.481
$0.541
52-Week Range:
$0.481
$3.39
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
0.4972 | 32.56M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Can Outlook Therapeutics Inc. reach all time highs this yearJuly 2025 Review & Low Risk High Reward Trade Ideas - mfd.ru
Bull Run: Will Outlook Therapeutics Inc outperform the market in YEARWeekly Market Report & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Profit Recap: Can Manhattan Associates Inc expand into new markets2025 Earnings Impact & Long-Term Investment Growth Plans - baoquankhu1.vn
Insider Trends: Is Outlook Therapeutics Inc stock a falling knife or bargain buy2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
US FDA declines to approve Outlook Therapeutics' eye disease drug - AOL.com
Will Outlook Therapeutics Inc. stock outperform international peersJuly 2025 Rallies & Free Real-Time Volume Trigger Notifications - ulpravda.ru
How Outlook Therapeutics Inc. (41ON) stock trades pre earnings2025 Price Momentum & Low Drawdown Trading Strategies - ulpravda.ru
How Outlook Therapeutics Inc. stock reacts to bond yieldsEarnings Performance Report & Accurate Entry and Exit Point Alerts - ulpravda.ru
Will Outlook Therapeutics Inc. (41O) stock beat revenue estimatesJuly 2025 Recap & Accurate Technical Buy Alerts - ulpravda.ru
Published on: 2026-01-09 04:38:07 - ulpravda.ru
What catalysts could drive Outlook Therapeutics Inc. stock higher2025 Performance Recap & Stepwise Trade Signal Implementation - ulpravda.ru
Published on: 2026-01-09 02:26:13 - ulpravda.ru
Is Outlook Therapeutics Inc. (41O) stock attractive for dividend growthMarket Risk Analysis & Fast Gain Swing Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:30 - Улправда
Is Outlook Therapeutics Inc. stock oversold or undervaluedM&A Rumor & Accurate Entry/Exit Alerts - ulpravda.ru
Outlook Therapeutics Appoints Laura Cantrell as VP of Corporate Strategy and Business Development - VisionMonday.com
Is Outlook Therapeutics Inc. stock vulnerable to regulatory risksStock Rotation Strategies & High Return Portfolio Growth - ulpravda.ru
Outlook Therapeutics Inc. trading halted, news pending - MSN
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - sharewise.com
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy By Investing.com - Investing.com Nigeria
Outlook Therapeutics appoints Laura Cantrell as VP of corporate strategy - Investing.com
Largest borrow rate increases among liquid names - TipRanks
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development - Quiver Quantitative
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset - MSN
FDA rejects Outlook Therapeutics' third BLA submission of bevacizumab for wet AMD - Eyes On Eyecare
Outlook Therapeutics price target lowered to 50c from $1 at HC Wainwright - MSN
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright - Investing.com Canada
Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright By Investing.com - Investing.com South Africa
Chardan Adjusts Price Target on Outlook Therapeutics to $1 From $3, Maintains Neutral Rating - marketscreener.com
OTLK: Chardan Capital Lowers Price Target, Maintains Neutral Rat - GuruFocus
What analysts say about Outlook Therapeutics Inc stockFlag and Pennant Patterns & Double Or Triple Wealth - earlytimes.in
Indegene Limited Included in Top Momentum ScanPortfolio Risk Assessment & Small Investment Big Gains - earlytimes.in
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics - TipRanks
What to keep an eye on in 2026 - Eyes On Eyecare
A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares - Stocktwits
Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Lifecore Biomedical (LFCR) - The Globe and Mail
OTLK: HC Wainwright Maintains Neutral Rating, Lowers Price Targe - GuruFocus
Outlook Therapeutics price target lowered to $1 from $3 at Chardan - TipRanks
Outlook Therapeutics plunges 60% as FDA denies Lytenava approval | Tap to know more | Inshorts - Inshorts
Outlook Therapeutics price target lowered to 50c from $1 at H.C. Wainwright - TipRanks
Missed window? A third CRL sinks Outlook’s ONS-5010 - BioWorld MedTech
Outlook Left Adrift With Another FDA Rejection For Lytenava - Citeline News & Insights
Regulatory tracker: Outlook Therapeutics' ophthalmic bevacizumab hit with another FDA rejection - Fierce Pharma
Outlook Therapeutics shares plunge 61.4% after US FDA declines to approve eye disease drug - MarketScreener
What analysts say about Outlook Therapeutics Inc 41ON stockSector Leadership Analysis & Small Investment Big Gains - earlytimes.in
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):